[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fDPl6VVs2-peE-dDjQQfMkX5Fkz8vp4h--bDoIOsXcMg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":8,"truncated":9,"activeTrials":10,"phase3Count":11,"totalEnrollment":12,"activePrograms":13,"nonDrugCount":14,"topConditions":15,"upcomingReadouts":36,"phaseBuckets":72,"rows":79},"PATH",[4,6,7],"PATH EX, Inc.","PATH Vaccine Solutions",116,false,8,11,272524,20,43,[16,19,21,23,26,29,32,34],{"name":17,"count":18},"Malaria",18,{"name":20,"count":11},"Influenza",{"name":22,"count":10},"Diarrhea",{"name":24,"count":25},"Poliomyelitis",6,{"name":27,"count":28},"G6PD Deficiency",4,{"name":30,"count":31},"Visceral Leishmaniasis",3,{"name":33,"count":31},"HIV",{"name":35,"count":31},"Pneumonia, Pneumococcal",[37,42,47,52,57,62,67],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06516042","Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia","2025-01-24","Dihydroartemisinin-piperaquine",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05644184","Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh","2026-05-15","Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT06895486","Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation","2026-12-28","Novel Oral Polio Vaccine Type 1",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06129916","Assessing the Acceptability, Feasibility, Effectiveness and Cost-effectiveness of LADB","2026-12-31","long-acting depot buprenorphine",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05654467","Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama","2027-03-20","Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT06879327","Infant Malaria Vaccine Schedule Optimization","2027-09-27","R21 Matrix-M (R21\u002FMM) Malaria Vaccine",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06137664","Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines","2027-12-15","Novel oral poliomyelitis vaccine type 1",[73,74,75,76,77,78],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[80,121,164,197,220,238,256,274,295,313,331,349,367,385,403,421,439,457,478,496,519,557,586,623,660,685,709,727,750,776,801,827,856,874,892,910,928,946,974,1002,1020,1038,1085,1117,1159,1190,1212,1230,1248,1274,1292,1310,1335,1359,1385,1403,1421,1469,1514,1542,1566,1584,1602,1620,1638,1656,1674,1699,1726,1744,1762,1788,1806,1832,1850,1868,1886,1904,1922,1940,1963,1981,1999,2017,2035,2053,2076,2111,2134,2161,2179,2197,2220,2242,2268,2286,2304,2322,2340,2364,2395,2413,2431,2449,2467,2485,2509,2531,2558,2576,2594,2612,2630,2648,2666,2688,2715,2733,2751,2788,2819,2845,2863,2886,2904,2928],{"intervention":41,"totalTrials":81,"cells":82},2,{"EARLY_PHASE1":83,"PHASE1":86,"PHASE2":88,"PHASE3":106,"PHASE4":117,"NA":119},{"trials":84,"activeCount":85},[],0,{"trials":87,"activeCount":85},[],{"trials":89,"activeCount":85},[90],{"nctId":91,"briefTitle":92,"status":93,"phases":94,"primaryCompletion":95,"completion":96,"start":97,"enrollment":98,"conditions":99,"interventions":101},"NCT04661579","Study of Malaria Vaccine RTS,S\u002FAS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy","COMPLETED",[75],"2022-06-22","2022-08-17","2020-11-06",620,[100],"Plasmodium Falciparum",[102,103,41,104,105],"Malaria Vaccine RTS,S\u002FAS01E","Abhayrab rabies vaccine","Artemether \u002F Lumefantrine","Primaquine",{"trials":107,"activeCount":116,"soonestReadout":40},[108],{"nctId":38,"briefTitle":39,"status":109,"phases":110,"primaryCompletion":40,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":115},"ACTIVE_NOT_RECRUITING",[76],"2025-07","2024-08-21",10350,[100,17],[41],1,{"trials":118,"activeCount":85},[],{"trials":120,"activeCount":85},[],{"intervention":122,"totalTrials":81,"cells":123},"Yellow Fever vaccine",{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":144,"PHASE4":146,"NA":162},{"trials":125,"activeCount":85},[],{"trials":127,"activeCount":85},[],{"trials":129,"activeCount":116,"soonestReadout":65},[130],{"nctId":63,"briefTitle":64,"status":131,"phases":132,"primaryCompletion":65,"completion":65,"start":133,"enrollment":134,"conditions":135,"interventions":137},"RECRUITING",[75],"2025-05-30",964,[136],"Malaria Vaccines",[66,138,139,140,141,142,122,143],"Hexavalent Vaccine","Pneumococcal Polysaccharide Conjugate Vaccine","Rotavirus, Live Attenuated (Oral) Vaccine","Measles and Rubella Vaccine","Meningococcal (A, C, Y, W, X) polysaccharide conjugate vaccine","Typhoid Conjugate vaccine",{"trials":145,"activeCount":85},[],{"trials":147,"activeCount":85},[148],{"nctId":149,"briefTitle":150,"status":93,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":157},"NCT02286895","Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali",[77],"2015-03","2014-10",600,[156],"Diarrhea Rotavirus",[158,159,160,161],"pentavalent rotavirus vaccine","measles vaccine","yellow fever vaccine","meningitis conjugate vaccine",{"trials":163,"activeCount":85},[],{"intervention":51,"totalTrials":81,"cells":165},{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":182,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":167,"activeCount":85},[],{"trials":169,"activeCount":85},[170],{"nctId":171,"briefTitle":172,"status":93,"phases":173,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":178},"NCT04529538","Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines",[74],"2023-02-17","2021-03-26",226,[24],[51,179,180,181],"Novel Oral Polio Vaccine Type 3","Sabin Monovalent Oral Polio Vaccine Type 1","Sabin Monovalent Oral Polio Vaccine Type 3",{"trials":183,"activeCount":116,"soonestReadout":50},[184],{"nctId":48,"briefTitle":49,"status":131,"phases":185,"primaryCompletion":50,"completion":50,"start":186,"enrollment":187,"conditions":188,"interventions":189},[75],"2025-11-11",675,[24],[51,190],"Novel Oral Polio Vaccine Type 2",{"trials":192,"activeCount":85},[],{"trials":194,"activeCount":85},[],{"trials":196,"activeCount":85},[],{"intervention":71,"totalTrials":116,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":214,"PHASE4":216,"NA":218},{"trials":200,"activeCount":85},[],{"trials":202,"activeCount":85},[],{"trials":204,"activeCount":116,"soonestReadout":70},[205],{"nctId":68,"briefTitle":69,"status":131,"phases":206,"primaryCompletion":70,"completion":70,"start":207,"enrollment":208,"conditions":209,"interventions":210},[74,75],"2024-11-20",2400,[24],[71,211,212,213],"Novel oral poliomyelitis vaccine type 2","Novel oral poliomyelitis vaccine type 3","Bivalent Oral Poliomyelitis Vaccine",{"trials":215,"activeCount":85},[],{"trials":217,"activeCount":85},[],{"trials":219,"activeCount":85},[],{"intervention":211,"totalTrials":116,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":232,"PHASE4":234,"NA":236},{"trials":223,"activeCount":85},[],{"trials":225,"activeCount":85},[],{"trials":227,"activeCount":116,"soonestReadout":70},[228],{"nctId":68,"briefTitle":69,"status":131,"phases":229,"primaryCompletion":70,"completion":70,"start":207,"enrollment":208,"conditions":230,"interventions":231},[74,75],[24],[71,211,212,213],{"trials":233,"activeCount":85},[],{"trials":235,"activeCount":85},[],{"trials":237,"activeCount":85},[],{"intervention":212,"totalTrials":116,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":250,"PHASE4":252,"NA":254},{"trials":241,"activeCount":85},[],{"trials":243,"activeCount":85},[],{"trials":245,"activeCount":116,"soonestReadout":70},[246],{"nctId":68,"briefTitle":69,"status":131,"phases":247,"primaryCompletion":70,"completion":70,"start":207,"enrollment":208,"conditions":248,"interventions":249},[74,75],[24],[71,211,212,213],{"trials":251,"activeCount":85},[],{"trials":253,"activeCount":85},[],{"trials":255,"activeCount":85},[],{"intervention":213,"totalTrials":116,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":268,"PHASE4":270,"NA":272},{"trials":259,"activeCount":85},[],{"trials":261,"activeCount":85},[],{"trials":263,"activeCount":116,"soonestReadout":70},[264],{"nctId":68,"briefTitle":69,"status":131,"phases":265,"primaryCompletion":70,"completion":70,"start":207,"enrollment":208,"conditions":266,"interventions":267},[74,75],[24],[71,211,212,213],{"trials":269,"activeCount":85},[],{"trials":271,"activeCount":85},[],{"trials":273,"activeCount":85},[],{"intervention":46,"totalTrials":116,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":277,"activeCount":85},[],{"trials":279,"activeCount":85},[],{"trials":281,"activeCount":116,"soonestReadout":45},[282],{"nctId":43,"briefTitle":44,"status":131,"phases":283,"primaryCompletion":45,"completion":45,"start":284,"enrollment":285,"conditions":286,"interventions":287},[75],"2023-03-27",2232,[24],[46,288],"Sabin Monovalent Oral Poliomyelitis Vaccine Type 1",{"trials":290,"activeCount":85},[],{"trials":292,"activeCount":85},[],{"trials":294,"activeCount":85},[],{"intervention":288,"totalTrials":116,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":307,"PHASE4":309,"NA":311},{"trials":298,"activeCount":85},[],{"trials":300,"activeCount":85},[],{"trials":302,"activeCount":116,"soonestReadout":45},[303],{"nctId":43,"briefTitle":44,"status":131,"phases":304,"primaryCompletion":45,"completion":45,"start":284,"enrollment":285,"conditions":305,"interventions":306},[75],[24],[46,288],{"trials":308,"activeCount":85},[],{"trials":310,"activeCount":85},[],{"trials":312,"activeCount":85},[],{"intervention":66,"totalTrials":116,"cells":314},{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":325,"PHASE4":327,"NA":329},{"trials":316,"activeCount":85},[],{"trials":318,"activeCount":85},[],{"trials":320,"activeCount":116,"soonestReadout":65},[321],{"nctId":63,"briefTitle":64,"status":131,"phases":322,"primaryCompletion":65,"completion":65,"start":133,"enrollment":134,"conditions":323,"interventions":324},[75],[136],[66,138,139,140,141,142,122,143],{"trials":326,"activeCount":85},[],{"trials":328,"activeCount":85},[],{"trials":330,"activeCount":85},[],{"intervention":138,"totalTrials":116,"cells":332},{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":343,"PHASE4":345,"NA":347},{"trials":334,"activeCount":85},[],{"trials":336,"activeCount":85},[],{"trials":338,"activeCount":116,"soonestReadout":65},[339],{"nctId":63,"briefTitle":64,"status":131,"phases":340,"primaryCompletion":65,"completion":65,"start":133,"enrollment":134,"conditions":341,"interventions":342},[75],[136],[66,138,139,140,141,142,122,143],{"trials":344,"activeCount":85},[],{"trials":346,"activeCount":85},[],{"trials":348,"activeCount":85},[],{"intervention":139,"totalTrials":116,"cells":350},{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":361,"PHASE4":363,"NA":365},{"trials":352,"activeCount":85},[],{"trials":354,"activeCount":85},[],{"trials":356,"activeCount":116,"soonestReadout":65},[357],{"nctId":63,"briefTitle":64,"status":131,"phases":358,"primaryCompletion":65,"completion":65,"start":133,"enrollment":134,"conditions":359,"interventions":360},[75],[136],[66,138,139,140,141,142,122,143],{"trials":362,"activeCount":85},[],{"trials":364,"activeCount":85},[],{"trials":366,"activeCount":85},[],{"intervention":140,"totalTrials":116,"cells":368},{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":379,"PHASE4":381,"NA":383},{"trials":370,"activeCount":85},[],{"trials":372,"activeCount":85},[],{"trials":374,"activeCount":116,"soonestReadout":65},[375],{"nctId":63,"briefTitle":64,"status":131,"phases":376,"primaryCompletion":65,"completion":65,"start":133,"enrollment":134,"conditions":377,"interventions":378},[75],[136],[66,138,139,140,141,142,122,143],{"trials":380,"activeCount":85},[],{"trials":382,"activeCount":85},[],{"trials":384,"activeCount":85},[],{"intervention":141,"totalTrials":116,"cells":386},{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":397,"PHASE4":399,"NA":401},{"trials":388,"activeCount":85},[],{"trials":390,"activeCount":85},[],{"trials":392,"activeCount":116,"soonestReadout":65},[393],{"nctId":63,"briefTitle":64,"status":131,"phases":394,"primaryCompletion":65,"completion":65,"start":133,"enrollment":134,"conditions":395,"interventions":396},[75],[136],[66,138,139,140,141,142,122,143],{"trials":398,"activeCount":85},[],{"trials":400,"activeCount":85},[],{"trials":402,"activeCount":85},[],{"intervention":142,"totalTrials":116,"cells":404},{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":415,"PHASE4":417,"NA":419},{"trials":406,"activeCount":85},[],{"trials":408,"activeCount":85},[],{"trials":410,"activeCount":116,"soonestReadout":65},[411],{"nctId":63,"briefTitle":64,"status":131,"phases":412,"primaryCompletion":65,"completion":65,"start":133,"enrollment":134,"conditions":413,"interventions":414},[75],[136],[66,138,139,140,141,142,122,143],{"trials":416,"activeCount":85},[],{"trials":418,"activeCount":85},[],{"trials":420,"activeCount":85},[],{"intervention":143,"totalTrials":116,"cells":422},{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":433,"PHASE4":435,"NA":437},{"trials":424,"activeCount":85},[],{"trials":426,"activeCount":85},[],{"trials":428,"activeCount":116,"soonestReadout":65},[429],{"nctId":63,"briefTitle":64,"status":131,"phases":430,"primaryCompletion":65,"completion":65,"start":133,"enrollment":134,"conditions":431,"interventions":432},[75],[136],[66,138,139,140,141,142,122,143],{"trials":434,"activeCount":85},[],{"trials":436,"activeCount":85},[],{"trials":438,"activeCount":85},[],{"intervention":190,"totalTrials":116,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":451,"PHASE4":453,"NA":455},{"trials":442,"activeCount":85},[],{"trials":444,"activeCount":85},[],{"trials":446,"activeCount":116,"soonestReadout":50},[447],{"nctId":48,"briefTitle":49,"status":131,"phases":448,"primaryCompletion":50,"completion":50,"start":186,"enrollment":187,"conditions":449,"interventions":450},[75],[24],[51,190],{"trials":452,"activeCount":85},[],{"trials":454,"activeCount":85},[],{"trials":456,"activeCount":85},[],{"intervention":61,"totalTrials":116,"cells":458},{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":472,"PHASE4":474,"NA":476},{"trials":460,"activeCount":85},[],{"trials":462,"activeCount":85},[],{"trials":464,"activeCount":116,"soonestReadout":60},[465],{"nctId":58,"briefTitle":59,"status":131,"phases":466,"primaryCompletion":60,"completion":60,"start":467,"enrollment":468,"conditions":469,"interventions":470},[75],"2023-12-05",1532,[24],[61,471],"Sabin Monovalent Oral Poliomyelitis Vaccine Type 3",{"trials":473,"activeCount":85},[],{"trials":475,"activeCount":85},[],{"trials":477,"activeCount":85},[],{"intervention":471,"totalTrials":116,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":490,"PHASE4":492,"NA":494},{"trials":481,"activeCount":85},[],{"trials":483,"activeCount":85},[],{"trials":485,"activeCount":116,"soonestReadout":60},[486],{"nctId":58,"briefTitle":59,"status":131,"phases":487,"primaryCompletion":60,"completion":60,"start":467,"enrollment":468,"conditions":488,"interventions":489},[75],[24],[61,471],{"trials":491,"activeCount":85},[],{"trials":493,"activeCount":85},[],{"trials":495,"activeCount":85},[],{"intervention":56,"totalTrials":116,"cells":497},{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":506,"NA":508},{"trials":499,"activeCount":85},[],{"trials":501,"activeCount":85},[],{"trials":503,"activeCount":85},[],{"trials":505,"activeCount":85},[],{"trials":507,"activeCount":85},[],{"trials":509,"activeCount":116,"soonestReadout":55},[510],{"nctId":53,"briefTitle":54,"status":511,"phases":512,"primaryCompletion":55,"completion":513,"start":514,"enrollment":515,"conditions":516,"interventions":518},"NOT_YET_RECRUITING",[],"2027-06-30","2025-11-01",760,[517],"Opioid Dependence",[56],{"intervention":520,"totalTrials":81,"cells":521},"Rotavirus vaccine",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":530,"NA":555},{"trials":523,"activeCount":85},[],{"trials":525,"activeCount":85},[],{"trials":527,"activeCount":85},[],{"trials":529,"activeCount":85},[],{"trials":531,"activeCount":85},[532,543],{"nctId":533,"briefTitle":534,"status":93,"phases":535,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":542},"NCT01199874","Immunogenicity of Rotavirus Vaccine",[77],"2012-09","2013-06","2011-04",1140,[541],"Rotavirus Gastroenteritis",[520],{"nctId":544,"briefTitle":545,"status":93,"phases":546,"primaryCompletion":547,"completion":547,"start":548,"enrollment":98,"conditions":549,"interventions":553},"NCT01616693","Zinc and\u002For Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines",[77],"2013-07","2012-07",[550,551,552],"Immunity to Oral Rotavirus Vaccine","Immunity to Oral Polio Vaccine","Shedding of Oral Rotavirus Vaccine",[520,554],"Oral polio vaccine",{"trials":556,"activeCount":85},[],{"intervention":159,"totalTrials":81,"cells":558},{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":565,"PHASE4":578,"NA":584},{"trials":560,"activeCount":85},[],{"trials":562,"activeCount":85},[],{"trials":564,"activeCount":85},[],{"trials":566,"activeCount":85},[567],{"nctId":568,"briefTitle":569,"status":93,"phases":570,"primaryCompletion":571,"completion":571,"start":572,"enrollment":154,"conditions":573,"interventions":575},"NCT00249769","Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine",[76],"2006-05-30","2005-11-21",[574],"Encephalitis, Japanese B",[576,577],"Live Japanese encephalitis vaccine SA 14-14-2","Measles Vaccine",{"trials":579,"activeCount":85},[580],{"nctId":149,"briefTitle":150,"status":93,"phases":581,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":582,"interventions":583},[77],[156],[158,159,160,161],{"trials":585,"activeCount":85},[],{"intervention":587,"totalTrials":81,"cells":588},"Seasonal trivalent inactivated influenza vaccine",{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":593,"PHASE3":606,"PHASE4":608,"NA":621},{"trials":590,"activeCount":85},[],{"trials":592,"activeCount":85},[],{"trials":594,"activeCount":85},[595],{"nctId":596,"briefTitle":597,"status":93,"phases":598,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":602,"interventions":603},"NCT01819155","Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa",[75],"2013-09","2013-04",296,[20],[604,587,605],"Adjuvanted seasonal trivalent inactivated influenza vaccine","Saline",{"trials":607,"activeCount":85},[],{"trials":609,"activeCount":85},[610],{"nctId":611,"briefTitle":612,"status":93,"phases":613,"primaryCompletion":614,"completion":600,"start":615,"enrollment":616,"conditions":617,"interventions":618},"NCT00893906","Inactivated Influenza Vaccine Effectiveness in Tropical Africa",[77],"2012-12","2009-05",10000,[20],[619,620],"seasonal trivalent inactivated influenza vaccine","inactivated polio vaccine",{"trials":622,"activeCount":85},[],{"intervention":624,"totalTrials":81,"cells":625},"Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine",{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":632,"PHASE4":634,"NA":658},{"trials":627,"activeCount":85},[],{"trials":629,"activeCount":85},[],{"trials":631,"activeCount":85},[],{"trials":633,"activeCount":85},[],{"trials":635,"activeCount":85},[636,648],{"nctId":637,"briefTitle":638,"status":93,"phases":639,"primaryCompletion":640,"completion":641,"start":642,"enrollment":643,"conditions":644,"interventions":646},"NCT00463684","Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age",[77],"2007-11-07","2008-10-06","2007-07-07",278,[645],"Japanese Encephalitis",[624,647],"Live, attenuated measles vaccine",{"nctId":649,"briefTitle":650,"status":93,"phases":651,"primaryCompletion":652,"completion":653,"start":654,"enrollment":655,"conditions":656,"interventions":657},"NCT00463476","Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine",[77],"2007-11-01","2008-10-02","2007-07-09",305,[645],[624],{"trials":659,"activeCount":85},[],{"intervention":661,"totalTrials":116,"cells":662},"Mebendazole",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":683},{"trials":664,"activeCount":85},[],{"trials":666,"activeCount":85},[],{"trials":668,"activeCount":85},[],{"trials":670,"activeCount":85},[],{"trials":672,"activeCount":85},[673],{"nctId":674,"briefTitle":675,"status":676,"phases":677,"primaryCompletion":678,"completion":678,"start":679,"enrollment":85,"conditions":680,"interventions":682},"NCT03261596","Mebendazole Study Against Hookworm Infections in Children and Adolescents in Ghana","WITHDRAWN",[77],"2017-12","2017-09",[681],"Hookworm Infections",[661],{"trials":684,"activeCount":85},[],{"intervention":686,"totalTrials":116,"cells":687},"Vaccine produced in existing facility",{"EARLY_PHASE1":688,"PHASE1":690,"PHASE2":692,"PHASE3":694,"PHASE4":696,"NA":707},{"trials":689,"activeCount":85},[],{"trials":691,"activeCount":85},[],{"trials":693,"activeCount":85},[],{"trials":695,"activeCount":85},[],{"trials":697,"activeCount":85},[698],{"nctId":699,"briefTitle":700,"status":93,"phases":701,"primaryCompletion":614,"completion":614,"start":702,"enrollment":703,"conditions":704,"interventions":705},"NCT01567865","Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine",[77],"2012-05",818,[645],[686,706],"Vaccine produced in new facility",{"trials":708,"activeCount":85},[],{"intervention":706,"totalTrials":116,"cells":710},{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":717,"PHASE4":719,"NA":725},{"trials":712,"activeCount":85},[],{"trials":714,"activeCount":85},[],{"trials":716,"activeCount":85},[],{"trials":718,"activeCount":85},[],{"trials":720,"activeCount":85},[721],{"nctId":699,"briefTitle":700,"status":93,"phases":722,"primaryCompletion":614,"completion":614,"start":702,"enrollment":703,"conditions":723,"interventions":724},[77],[645],[686,706],{"trials":726,"activeCount":85},[],{"intervention":728,"totalTrials":116,"cells":729},"Human Rotavirus Vaccine",{"EARLY_PHASE1":730,"PHASE1":732,"PHASE2":734,"PHASE3":736,"PHASE4":738,"NA":748},{"trials":731,"activeCount":85},[],{"trials":733,"activeCount":85},[],{"trials":735,"activeCount":85},[],{"trials":737,"activeCount":85},[],{"trials":739,"activeCount":85},[740],{"nctId":741,"briefTitle":742,"status":93,"phases":743,"primaryCompletion":744,"completion":744,"start":536,"enrollment":745,"conditions":746,"interventions":747},"NCT01575197","Evaluation of the Human Rotavirus Vaccine at Varying Schedules and Doses in Rural Ghana",[77],"2013-02",456,[541],[728],{"trials":749,"activeCount":85},[],{"intervention":751,"totalTrials":116,"cells":752},"Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine",{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":759,"PHASE4":761,"NA":774},{"trials":754,"activeCount":85},[],{"trials":756,"activeCount":85},[],{"trials":758,"activeCount":85},[],{"trials":760,"activeCount":85},[],{"trials":762,"activeCount":85},[763],{"nctId":764,"briefTitle":765,"status":93,"phases":766,"primaryCompletion":767,"completion":768,"start":769,"enrollment":770,"conditions":771,"interventions":773},"NCT02514746","Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose",[77],"2016-12-15","2017-01-12","2015-07-30",561,[772],"Encephalitis, Japanese",[751],{"trials":775,"activeCount":85},[],{"intervention":777,"totalTrials":116,"cells":778},"Reactive Focal Drug Administration",{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":785,"PHASE4":787,"NA":799},{"trials":780,"activeCount":85},[],{"trials":782,"activeCount":85},[],{"trials":784,"activeCount":85},[],{"trials":786,"activeCount":85},[],{"trials":788,"activeCount":85},[789],{"nctId":790,"briefTitle":791,"status":93,"phases":792,"primaryCompletion":793,"completion":794,"start":795,"enrollment":796,"conditions":797,"interventions":798},"NCT02654912","Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration",[77],"2020-06","2020-07","2016-02",8682,[17],[777],{"trials":800,"activeCount":85},[],{"intervention":802,"totalTrials":116,"cells":803},"Intervention package",{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":808,"PHASE3":810,"PHASE4":812,"NA":825},{"trials":805,"activeCount":85},[],{"trials":807,"activeCount":85},[],{"trials":809,"activeCount":85},[],{"trials":811,"activeCount":85},[],{"trials":813,"activeCount":85},[814],{"nctId":815,"briefTitle":816,"status":817,"phases":818,"primaryCompletion":819,"completion":820,"start":821,"enrollment":822,"conditions":823,"interventions":824},"NCT06225297","Evaluation of Vector and Chemoprevention-based Interventions to Reduce Malaria Burden in Urban Daaras of Touba, Senegal","SUSPENDED",[77],"2024-12-23","2025-02","2024-01-19",4600,[17],[802],{"trials":826,"activeCount":85},[],{"intervention":828,"totalTrials":116,"cells":829},"Live attenuated SA 14-14-2 Japanese Encephalitis vaccine",{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":838,"NA":854},{"trials":831,"activeCount":85},[],{"trials":833,"activeCount":85},[],{"trials":835,"activeCount":85},[],{"trials":837,"activeCount":85},[],{"trials":839,"activeCount":85},[840],{"nctId":841,"briefTitle":842,"status":93,"phases":843,"primaryCompletion":844,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":852},"NCT02880865","Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine",[77],"2017-05-19","2017-07-11","2016-10-13",628,[772,849,850,851],"Measles","Mumps","Rubella",[828,853],"Measles, mumps, rubella vaccine",{"trials":855,"activeCount":85},[],{"intervention":853,"totalTrials":116,"cells":857},{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":864,"PHASE4":866,"NA":872},{"trials":859,"activeCount":85},[],{"trials":861,"activeCount":85},[],{"trials":863,"activeCount":85},[],{"trials":865,"activeCount":85},[],{"trials":867,"activeCount":85},[868],{"nctId":841,"briefTitle":842,"status":93,"phases":869,"primaryCompletion":844,"completion":845,"start":846,"enrollment":847,"conditions":870,"interventions":871},[77],[772,849,850,851],[828,853],{"trials":873,"activeCount":85},[],{"intervention":554,"totalTrials":116,"cells":875},{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":882,"PHASE4":884,"NA":890},{"trials":877,"activeCount":85},[],{"trials":879,"activeCount":85},[],{"trials":881,"activeCount":85},[],{"trials":883,"activeCount":85},[],{"trials":885,"activeCount":85},[886],{"nctId":544,"briefTitle":545,"status":93,"phases":887,"primaryCompletion":547,"completion":547,"start":548,"enrollment":98,"conditions":888,"interventions":889},[77],[550,551,552],[520,554],{"trials":891,"activeCount":85},[],{"intervention":158,"totalTrials":116,"cells":893},{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":900,"PHASE4":902,"NA":908},{"trials":895,"activeCount":85},[],{"trials":897,"activeCount":85},[],{"trials":899,"activeCount":85},[],{"trials":901,"activeCount":85},[],{"trials":903,"activeCount":85},[904],{"nctId":149,"briefTitle":150,"status":93,"phases":905,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":906,"interventions":907},[77],[156],[158,159,160,161],{"trials":909,"activeCount":85},[],{"intervention":161,"totalTrials":116,"cells":911},{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":920,"NA":926},{"trials":913,"activeCount":85},[],{"trials":915,"activeCount":85},[],{"trials":917,"activeCount":85},[],{"trials":919,"activeCount":85},[],{"trials":921,"activeCount":85},[922],{"nctId":149,"briefTitle":150,"status":93,"phases":923,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":924,"interventions":925},[77],[156],[158,159,160,161],{"trials":927,"activeCount":85},[],{"intervention":647,"totalTrials":116,"cells":929},{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":936,"PHASE4":938,"NA":944},{"trials":931,"activeCount":85},[],{"trials":933,"activeCount":85},[],{"trials":935,"activeCount":85},[],{"trials":937,"activeCount":85},[],{"trials":939,"activeCount":85},[940],{"nctId":637,"briefTitle":638,"status":93,"phases":941,"primaryCompletion":640,"completion":641,"start":642,"enrollment":643,"conditions":942,"interventions":943},[77],[645],[624,647],{"trials":945,"activeCount":85},[],{"intervention":947,"totalTrials":116,"cells":948},"chloroquine + primaquine",{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":972},{"trials":950,"activeCount":85},[],{"trials":952,"activeCount":85},[],{"trials":954,"activeCount":85},[],{"trials":956,"activeCount":85},[],{"trials":958,"activeCount":85},[959],{"nctId":960,"briefTitle":961,"status":962,"phases":963,"primaryCompletion":964,"completion":965,"start":966,"enrollment":967,"conditions":968,"interventions":970},"NCT03337152","Assessing a Risk Model for G6PD Deficiency","TERMINATED",[77],"2018-08-21","2018-10-21","2018-05-07",54,[969,27],"Malaria, Vivax",[971,947],"primaquine",{"trials":973,"activeCount":85},[],{"intervention":975,"totalTrials":116,"cells":976},"Rotarix vaccine",{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":983,"PHASE4":985,"NA":1000},{"trials":978,"activeCount":85},[],{"trials":980,"activeCount":85},[],{"trials":982,"activeCount":85},[],{"trials":984,"activeCount":85},[],{"trials":986,"activeCount":85},[987],{"nctId":988,"briefTitle":989,"status":93,"phases":990,"primaryCompletion":599,"completion":599,"start":991,"enrollment":992,"conditions":993,"interventions":998},"NCT01700621","Coadministration of Measles-rubella and Rotavirus Vaccines",[77],"2013-01",482,[994,995,996,997],"Measles Antibody Seroconversion","Rubella Antibody Seroconversion","Rotavirus Geometric Mean Titer (GMT)","Rotavirus Immunoglobulin A (IgA) Seropositivity",[975,999],"measles-rubella vaccine",{"trials":1001,"activeCount":85},[],{"intervention":999,"totalTrials":116,"cells":1003},{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1010,"PHASE4":1012,"NA":1018},{"trials":1005,"activeCount":85},[],{"trials":1007,"activeCount":85},[],{"trials":1009,"activeCount":85},[],{"trials":1011,"activeCount":85},[],{"trials":1013,"activeCount":85},[1014],{"nctId":988,"briefTitle":989,"status":93,"phases":1015,"primaryCompletion":599,"completion":599,"start":991,"enrollment":992,"conditions":1016,"interventions":1017},[77],[994,995,996,997],[975,999],{"trials":1019,"activeCount":85},[],{"intervention":620,"totalTrials":116,"cells":1021},{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1028,"PHASE4":1030,"NA":1036},{"trials":1023,"activeCount":85},[],{"trials":1025,"activeCount":85},[],{"trials":1027,"activeCount":85},[],{"trials":1029,"activeCount":85},[],{"trials":1031,"activeCount":85},[1032],{"nctId":611,"briefTitle":612,"status":93,"phases":1033,"primaryCompletion":614,"completion":600,"start":615,"enrollment":616,"conditions":1034,"interventions":1035},[77],[20],[619,620],{"trials":1037,"activeCount":85},[],{"intervention":1039,"totalTrials":31,"cells":1040},"Synflorix",{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1058,"PHASE4":1081,"NA":1083},{"trials":1042,"activeCount":85},[],{"trials":1044,"activeCount":85},[],{"trials":1046,"activeCount":85},[1047],{"nctId":1048,"briefTitle":1049,"status":93,"phases":1050,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1055},"NCT02097472","Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers",[74,75],"2015-12","2014-04",304,[35],[1056,1039,1057],"PATH-wSP","Pentavac",{"trials":1059,"activeCount":85},[1060,1071],{"nctId":1061,"briefTitle":1062,"status":93,"phases":1063,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":1067,"conditions":1068,"interventions":1069},"NCT03197376","Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants",[76],"2018-06-06","2019-05-09","2017-06-21",2250,[35],[1070,1039],"Pneumosil",{"nctId":1072,"briefTitle":1073,"status":93,"phases":1074,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1079},"NCT03896477","Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants",[76],"2020-12-17","2019-07-18",660,[35],[1070,1080,1039],"Prevenar 13",{"trials":1082,"activeCount":85},[],{"trials":1084,"activeCount":85},[],{"intervention":1086,"totalTrials":81,"cells":1087},"SIIL Live Attenuated Influenza Vaccine",{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1094,"PHASE4":1113,"NA":1115},{"trials":1089,"activeCount":85},[],{"trials":1091,"activeCount":85},[],{"trials":1093,"activeCount":85},[],{"trials":1095,"activeCount":85},[1096,1106],{"nctId":1097,"briefTitle":1098,"status":93,"phases":1099,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1103,"interventions":1104},"NCT01854632","Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal",[76],"2013-12","2013-05",1761,[20],[1086,1105],"Matched placebo",{"nctId":1107,"briefTitle":1108,"status":93,"phases":1109,"primaryCompletion":1110,"completion":1110,"start":744,"enrollment":1102,"conditions":1111,"interventions":1112},"NCT01797029","A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh",[76],"2014-09",[20],[1086],{"trials":1114,"activeCount":85},[],{"trials":1116,"activeCount":85},[],{"intervention":1118,"totalTrials":81,"cells":1119},"Rotarix",{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1141,"PHASE4":1155,"NA":1157},{"trials":1121,"activeCount":85},[],{"trials":1123,"activeCount":85},[],{"trials":1125,"activeCount":85},[1126],{"nctId":1127,"briefTitle":1128,"status":93,"phases":1129,"primaryCompletion":1130,"completion":1131,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1136},"NCT04344054","Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine",[75],"2022-09-06","2022-09-09","2021-02-22",850,[1135],"Rotavirus Vaccine",[1137,1138,1118,1139,1140],"RV3-BB","Trivalent P2-VP8","RV3-BB birth dose","Trivalent P2-VP8 Booster dose",{"trials":1142,"activeCount":85},[1143],{"nctId":1144,"briefTitle":1145,"status":1146,"phases":1147,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":1150,"conditions":1151,"interventions":1153},"NCT04010448","A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India","UNKNOWN",[76],"2025-12-15","2019-10-10",8200,[1152],"Rotavirus Infection of Children",[1154,1118],"TV P2-VP8",{"trials":1156,"activeCount":85},[],{"trials":1158,"activeCount":85},[],{"intervention":1080,"totalTrials":81,"cells":1160},{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1180,"PHASE4":1186,"NA":1188},{"trials":1162,"activeCount":85},[],{"trials":1164,"activeCount":85},[],{"trials":1166,"activeCount":85},[1167],{"nctId":1168,"briefTitle":1169,"status":93,"phases":1170,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":1174,"conditions":1175,"interventions":1177},"NCT02308540","Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants",[74,75],"2016-04","2016-11-03","2015-01-12",346,[1176],"Pneumococcal Disease",[1178,1179,1080],"SIILPCV10","Pneumovax 23",{"trials":1181,"activeCount":85},[1182],{"nctId":1072,"briefTitle":1073,"status":93,"phases":1183,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1184,"interventions":1185},[76],[35],[1070,1080,1039],{"trials":1187,"activeCount":85},[],{"trials":1189,"activeCount":85},[],{"intervention":1070,"totalTrials":81,"cells":1191},{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1196,"PHASE3":1198,"PHASE4":1208,"NA":1210},{"trials":1193,"activeCount":85},[],{"trials":1195,"activeCount":85},[],{"trials":1197,"activeCount":85},[],{"trials":1199,"activeCount":85},[1200,1204],{"nctId":1061,"briefTitle":1062,"status":93,"phases":1201,"primaryCompletion":1064,"completion":1065,"start":1066,"enrollment":1067,"conditions":1202,"interventions":1203},[76],[35],[1070,1039],{"nctId":1072,"briefTitle":1073,"status":93,"phases":1205,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1206,"interventions":1207},[76],[35],[1070,1080,1039],{"trials":1209,"activeCount":85},[],{"trials":1211,"activeCount":85},[],{"intervention":1105,"totalTrials":116,"cells":1213},{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1226,"NA":1228},{"trials":1215,"activeCount":85},[],{"trials":1217,"activeCount":85},[],{"trials":1219,"activeCount":85},[],{"trials":1221,"activeCount":85},[1222],{"nctId":1097,"briefTitle":1098,"status":93,"phases":1223,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1224,"interventions":1225},[76],[20],[1086,1105],{"trials":1227,"activeCount":85},[],{"trials":1229,"activeCount":85},[],{"intervention":1154,"totalTrials":116,"cells":1231},{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1238,"PHASE4":1244,"NA":1246},{"trials":1233,"activeCount":85},[],{"trials":1235,"activeCount":85},[],{"trials":1237,"activeCount":85},[],{"trials":1239,"activeCount":85},[1240],{"nctId":1144,"briefTitle":1145,"status":1146,"phases":1241,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":1150,"conditions":1242,"interventions":1243},[76],[1152],[1154,1118],{"trials":1245,"activeCount":85},[],{"trials":1247,"activeCount":85},[],{"intervention":1249,"totalTrials":116,"cells":1250},"BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1",{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1255,"PHASE3":1257,"PHASE4":1270,"NA":1272},{"trials":1252,"activeCount":85},[],{"trials":1254,"activeCount":85},[],{"trials":1256,"activeCount":85},[],{"trials":1258,"activeCount":85},[1259],{"nctId":1260,"briefTitle":1261,"status":93,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":1265,"conditions":1266,"interventions":1267},"NCT02434770","Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine",[76],"2016-06-17","2015-08",750,[24],[1249,1268,1269],"BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2","BioFarma Bivalent Oral Poliomyelitis Vaccine",{"trials":1271,"activeCount":85},[],{"trials":1273,"activeCount":85},[],{"intervention":1268,"totalTrials":116,"cells":1275},{"EARLY_PHASE1":1276,"PHASE1":1278,"PHASE2":1280,"PHASE3":1282,"PHASE4":1288,"NA":1290},{"trials":1277,"activeCount":85},[],{"trials":1279,"activeCount":85},[],{"trials":1281,"activeCount":85},[],{"trials":1283,"activeCount":85},[1284],{"nctId":1260,"briefTitle":1261,"status":93,"phases":1285,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":1265,"conditions":1286,"interventions":1287},[76],[24],[1249,1268,1269],{"trials":1289,"activeCount":85},[],{"trials":1291,"activeCount":85},[],{"intervention":1269,"totalTrials":116,"cells":1293},{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1298,"PHASE3":1300,"PHASE4":1306,"NA":1308},{"trials":1295,"activeCount":85},[],{"trials":1297,"activeCount":85},[],{"trials":1299,"activeCount":85},[],{"trials":1301,"activeCount":85},[1302],{"nctId":1260,"briefTitle":1261,"status":93,"phases":1303,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":1265,"conditions":1304,"interventions":1305},[76],[24],[1249,1268,1269],{"trials":1307,"activeCount":85},[],{"trials":1309,"activeCount":85},[],{"intervention":1311,"totalTrials":116,"cells":1312},"Amphotericin B",{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1319,"PHASE4":1331,"NA":1333},{"trials":1314,"activeCount":85},[],{"trials":1316,"activeCount":85},[],{"trials":1318,"activeCount":85},[],{"trials":1320,"activeCount":85},[1321],{"nctId":1322,"briefTitle":1323,"status":93,"phases":1324,"completion":1325,"start":1326,"enrollment":1327,"conditions":1328,"interventions":1329},"NCT00216346","Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis",[76],"2004-11","2003-06",667,[30],[1330,1311],"Paromomycin sulfate",{"trials":1332,"activeCount":85},[],{"trials":1334,"activeCount":85},[],{"intervention":1336,"totalTrials":116,"cells":1337},"Live attenuated SA 14-14-2 vaccine",{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1344,"PHASE4":1355,"NA":1357},{"trials":1339,"activeCount":85},[],{"trials":1341,"activeCount":85},[],{"trials":1343,"activeCount":85},[],{"trials":1345,"activeCount":85},[1346],{"nctId":1347,"briefTitle":1348,"status":93,"phases":1349,"primaryCompletion":1350,"completion":1350,"start":1351,"enrollment":1352,"conditions":1353,"interventions":1354},"NCT00412516","Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine",[76],"2010-03","2006-12",519,[574],[1336],{"trials":1356,"activeCount":85},[],{"trials":1358,"activeCount":85},[],{"intervention":1360,"totalTrials":116,"cells":1361},"Cecolin®",{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1366,"PHASE3":1368,"PHASE4":1381,"NA":1383},{"trials":1363,"activeCount":85},[],{"trials":1365,"activeCount":85},[],{"trials":1367,"activeCount":85},[],{"trials":1369,"activeCount":85},[1370],{"nctId":1371,"briefTitle":1372,"status":93,"phases":1373,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":1376,"conditions":1377,"interventions":1379},"NCT04508309","Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls",[76],"2023-12-14","2021-03-15",1025,[1378],"Cervical Cancer",[1360,1380],"Gardasil®",{"trials":1382,"activeCount":85},[],{"trials":1384,"activeCount":85},[],{"intervention":1380,"totalTrials":116,"cells":1386},{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1393,"PHASE4":1399,"NA":1401},{"trials":1388,"activeCount":85},[],{"trials":1390,"activeCount":85},[],{"trials":1392,"activeCount":85},[],{"trials":1394,"activeCount":85},[1395],{"nctId":1371,"briefTitle":1372,"status":93,"phases":1396,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":1376,"conditions":1397,"interventions":1398},[76],[1378],[1360,1380],{"trials":1400,"activeCount":85},[],{"trials":1402,"activeCount":85},[],{"intervention":576,"totalTrials":116,"cells":1404},{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1409,"PHASE3":1411,"PHASE4":1417,"NA":1419},{"trials":1406,"activeCount":85},[],{"trials":1408,"activeCount":85},[],{"trials":1410,"activeCount":85},[],{"trials":1412,"activeCount":85},[1413],{"nctId":568,"briefTitle":569,"status":93,"phases":1414,"primaryCompletion":571,"completion":571,"start":572,"enrollment":154,"conditions":1415,"interventions":1416},[76],[574],[576,577],{"trials":1418,"activeCount":85},[],{"trials":1420,"activeCount":85},[],{"intervention":1422,"totalTrials":31,"cells":1423},"dmLT",{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1438,"PHASE3":1463,"PHASE4":1465,"NA":1467},{"trials":1425,"activeCount":85},[],{"trials":1427,"activeCount":85},[1428],{"nctId":1429,"briefTitle":1430,"status":93,"phases":1431,"primaryCompletion":1432,"completion":1432,"start":1433,"enrollment":1434,"conditions":1435,"interventions":1436},"NCT03404674","Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)",[74],"2019-03-26","2018-01-16",50,[22],[1437,1422],"CssBA",{"trials":1439,"activeCount":85},[1440,1451],{"nctId":1441,"briefTitle":1442,"status":93,"phases":1443,"primaryCompletion":1444,"completion":1444,"start":1445,"enrollment":1446,"conditions":1447,"interventions":1449},"NCT02531802","Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh",[74,75],"2017-07-29","2015-10",475,[1448],"Escherichia Coli Diarrhea",[1450,1422],"ETVAX",{"nctId":1452,"briefTitle":1453,"status":93,"phases":1454,"primaryCompletion":1455,"completion":1456,"start":536,"enrollment":1457,"conditions":1458,"interventions":1459},"NCT01739231","Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults",[74,75],"2013-10","2014-01",81,[22],[1460,1422,1461,1462],"ACE527","CeraVacx placebo","H10407 challenge strain",{"trials":1464,"activeCount":85},[],{"trials":1466,"activeCount":85},[],{"trials":1468,"activeCount":85},[],{"intervention":1470,"totalTrials":31,"cells":1471},"iOWH032",{"EARLY_PHASE1":1472,"PHASE1":1474,"PHASE2":1486,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1473,"activeCount":85},[],{"trials":1475,"activeCount":85},[1476],{"nctId":1477,"briefTitle":1478,"status":93,"phases":1479,"primaryCompletion":1480,"completion":1481,"start":1101,"enrollment":1482,"conditions":1483,"interventions":1485},"NCT01823939","PK Study of iOWH032 in Adult Male\u002FFemale Healthy Volunteers & Adult Males With Cholera",[74],"2013-11","2014-12",26,[22,1484],"Cholera",[1470],{"trials":1487,"activeCount":85},[1488,1498],{"nctId":1489,"briefTitle":1490,"status":93,"phases":1491,"primaryCompletion":1492,"completion":1492,"start":1493,"enrollment":1494,"conditions":1495,"interventions":1496},"NCT04150250","Cholera Anti-Secretory Treatment Trial",[75],"2020-07-27","2019-11-04",47,[1484],[1470,1497],"Antibiotics",{"nctId":1499,"briefTitle":1500,"status":676,"phases":1501,"primaryCompletion":1502,"completion":1503,"start":1504,"enrollment":85,"conditions":1505,"interventions":1507},"NCT02111304","Efficacy of iOWH032 in Dehydrating Cholera",[75],"2016-01","2016-05","2014-06",[1506],"Secretory Diarrhea",[1470],{"trials":1509,"activeCount":85},[],{"trials":1511,"activeCount":85},[],{"trials":1513,"activeCount":85},[],{"intervention":1056,"totalTrials":81,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1536,"PHASE4":1538,"NA":1540},{"trials":1517,"activeCount":85},[],{"trials":1519,"activeCount":85},[],{"trials":1521,"activeCount":85},[1522,1526],{"nctId":1048,"briefTitle":1049,"status":93,"phases":1523,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":1053,"conditions":1524,"interventions":1525},[74,75],[35],[1056,1039,1057],{"nctId":1527,"briefTitle":1528,"status":93,"phases":1529,"primaryCompletion":1530,"completion":1530,"start":1531,"enrollment":1532,"conditions":1533,"interventions":1535},"NCT02543892","A Study of a Vaccine for Pneumonia in Adults and Toddlers in Kenya",[74,75],"2018-01-04","2016-08-10",248,[1534],"Pneumonia",[1056],{"trials":1537,"activeCount":85},[],{"trials":1539,"activeCount":85},[],{"trials":1541,"activeCount":85},[],{"intervention":1543,"totalTrials":116,"cells":1544},"Fluzone Influenza Vaccine",{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1549,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1546,"activeCount":85},[],{"trials":1548,"activeCount":85},[],{"trials":1550,"activeCount":85},[1551],{"nctId":1552,"briefTitle":1553,"status":93,"phases":1554,"primaryCompletion":1555,"completion":1555,"start":1556,"enrollment":1557,"conditions":1558,"interventions":1559},"NCT00504231","Intradermal Influenza Vaccine Study in Elders",[75],"2008-01","2007-09",257,[20],[1543],{"trials":1561,"activeCount":85},[],{"trials":1563,"activeCount":85},[],{"trials":1565,"activeCount":85},[],{"intervention":1450,"totalTrials":116,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1578,"PHASE4":1580,"NA":1582},{"trials":1569,"activeCount":85},[],{"trials":1571,"activeCount":85},[],{"trials":1573,"activeCount":85},[1574],{"nctId":1441,"briefTitle":1442,"status":93,"phases":1575,"primaryCompletion":1444,"completion":1444,"start":1445,"enrollment":1446,"conditions":1576,"interventions":1577},[74,75],[1448],[1450,1422],{"trials":1579,"activeCount":85},[],{"trials":1581,"activeCount":85},[],{"trials":1583,"activeCount":85},[],{"intervention":1057,"totalTrials":116,"cells":1585},{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1596,"PHASE4":1598,"NA":1600},{"trials":1587,"activeCount":85},[],{"trials":1589,"activeCount":85},[],{"trials":1591,"activeCount":85},[1592],{"nctId":1048,"briefTitle":1049,"status":93,"phases":1593,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":1053,"conditions":1594,"interventions":1595},[74,75],[35],[1056,1039,1057],{"trials":1597,"activeCount":85},[],{"trials":1599,"activeCount":85},[],{"trials":1601,"activeCount":85},[],{"intervention":1497,"totalTrials":116,"cells":1603},{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1614,"PHASE4":1616,"NA":1618},{"trials":1605,"activeCount":85},[],{"trials":1607,"activeCount":85},[],{"trials":1609,"activeCount":85},[1610],{"nctId":1489,"briefTitle":1490,"status":93,"phases":1611,"primaryCompletion":1492,"completion":1492,"start":1493,"enrollment":1494,"conditions":1612,"interventions":1613},[75],[1484],[1470,1497],{"trials":1615,"activeCount":85},[],{"trials":1617,"activeCount":85},[],{"trials":1619,"activeCount":85},[],{"intervention":102,"totalTrials":116,"cells":1621},{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1632,"PHASE4":1634,"NA":1636},{"trials":1623,"activeCount":85},[],{"trials":1625,"activeCount":85},[],{"trials":1627,"activeCount":85},[1628],{"nctId":91,"briefTitle":92,"status":93,"phases":1629,"primaryCompletion":95,"completion":96,"start":97,"enrollment":98,"conditions":1630,"interventions":1631},[75],[100],[102,103,41,104,105],{"trials":1633,"activeCount":85},[],{"trials":1635,"activeCount":85},[],{"trials":1637,"activeCount":85},[],{"intervention":103,"totalTrials":116,"cells":1639},{"EARLY_PHASE1":1640,"PHASE1":1642,"PHASE2":1644,"PHASE3":1650,"PHASE4":1652,"NA":1654},{"trials":1641,"activeCount":85},[],{"trials":1643,"activeCount":85},[],{"trials":1645,"activeCount":85},[1646],{"nctId":91,"briefTitle":92,"status":93,"phases":1647,"primaryCompletion":95,"completion":96,"start":97,"enrollment":98,"conditions":1648,"interventions":1649},[75],[100],[102,103,41,104,105],{"trials":1651,"activeCount":85},[],{"trials":1653,"activeCount":85},[],{"trials":1655,"activeCount":85},[],{"intervention":104,"totalTrials":116,"cells":1657},{"EARLY_PHASE1":1658,"PHASE1":1660,"PHASE2":1662,"PHASE3":1668,"PHASE4":1670,"NA":1672},{"trials":1659,"activeCount":85},[],{"trials":1661,"activeCount":85},[],{"trials":1663,"activeCount":85},[1664],{"nctId":91,"briefTitle":92,"status":93,"phases":1665,"primaryCompletion":95,"completion":96,"start":97,"enrollment":98,"conditions":1666,"interventions":1667},[75],[100],[102,103,41,104,105],{"trials":1669,"activeCount":85},[],{"trials":1671,"activeCount":85},[],{"trials":1673,"activeCount":85},[],{"intervention":1675,"totalTrials":116,"cells":1676},"Rilpivirine",{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1681,"PHASE3":1693,"PHASE4":1695,"NA":1697},{"trials":1678,"activeCount":85},[],{"trials":1680,"activeCount":85},[],{"trials":1682,"activeCount":85},[1683],{"nctId":1684,"briefTitle":1685,"status":93,"phases":1686,"primaryCompletion":1687,"completion":1688,"start":153,"enrollment":1689,"conditions":1690,"interventions":1692},"NCT02165202","Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis",[75],"2015-04-13","2017-03-09",136,[1691],"Human Immunodeficiency Virus (HIV)",[1675],{"trials":1694,"activeCount":85},[],{"trials":1696,"activeCount":85},[],{"trials":1698,"activeCount":85},[],{"intervention":1700,"totalTrials":116,"cells":1701},"P2-VP8 Subunit Vaccine 10mcg",{"EARLY_PHASE1":1702,"PHASE1":1704,"PHASE2":1706,"PHASE3":1720,"PHASE4":1722,"NA":1724},{"trials":1703,"activeCount":85},[],{"trials":1705,"activeCount":85},[],{"trials":1707,"activeCount":85},[1708],{"nctId":1709,"briefTitle":1710,"status":93,"phases":1711,"primaryCompletion":1712,"completion":1712,"start":1713,"enrollment":1714,"conditions":1715,"interventions":1717},"NCT02109484","Phase I\u002FII Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants",[74,75],"2015-11","2014-03",204,[1716],"Evaluation of a Rotavirus Vaccine",[1700,1718,1719],"P2-VP8 Subunit Vaccine 30 mcg","P2-VP8 Subunit Vaccine 60mcg",{"trials":1721,"activeCount":85},[],{"trials":1723,"activeCount":85},[],{"trials":1725,"activeCount":85},[],{"intervention":1718,"totalTrials":116,"cells":1727},{"EARLY_PHASE1":1728,"PHASE1":1730,"PHASE2":1732,"PHASE3":1738,"PHASE4":1740,"NA":1742},{"trials":1729,"activeCount":85},[],{"trials":1731,"activeCount":85},[],{"trials":1733,"activeCount":85},[1734],{"nctId":1709,"briefTitle":1710,"status":93,"phases":1735,"primaryCompletion":1712,"completion":1712,"start":1713,"enrollment":1714,"conditions":1736,"interventions":1737},[74,75],[1716],[1700,1718,1719],{"trials":1739,"activeCount":85},[],{"trials":1741,"activeCount":85},[],{"trials":1743,"activeCount":85},[],{"intervention":1719,"totalTrials":116,"cells":1745},{"EARLY_PHASE1":1746,"PHASE1":1748,"PHASE2":1750,"PHASE3":1756,"PHASE4":1758,"NA":1760},{"trials":1747,"activeCount":85},[],{"trials":1749,"activeCount":85},[],{"trials":1751,"activeCount":85},[1752],{"nctId":1709,"briefTitle":1710,"status":93,"phases":1753,"primaryCompletion":1712,"completion":1712,"start":1713,"enrollment":1714,"conditions":1754,"interventions":1755},[74,75],[1716],[1700,1718,1719],{"trials":1757,"activeCount":85},[],{"trials":1759,"activeCount":85},[],{"trials":1761,"activeCount":85},[],{"intervention":1763,"totalTrials":116,"cells":1764},"Shigella flexneri 2a whole cell",{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1782,"PHASE4":1784,"NA":1786},{"trials":1766,"activeCount":85},[],{"trials":1768,"activeCount":85},[],{"trials":1770,"activeCount":85},[1771],{"nctId":1772,"briefTitle":1773,"status":676,"phases":1774,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":85,"conditions":1778,"interventions":1780},"NCT03038243","Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults",[75],"2018-12-31","2019-12-31","2017-08-01",[1779],"Shigella Sonnei Dysenteries",[1763,1781],"Shigella flexneri 2a whole cell (Sf2aWC) vaccine",{"trials":1783,"activeCount":85},[],{"trials":1785,"activeCount":85},[],{"trials":1787,"activeCount":85},[],{"intervention":1781,"totalTrials":116,"cells":1789},{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1800,"PHASE4":1802,"NA":1804},{"trials":1791,"activeCount":85},[],{"trials":1793,"activeCount":85},[],{"trials":1795,"activeCount":85},[1796],{"nctId":1772,"briefTitle":1773,"status":676,"phases":1797,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":85,"conditions":1798,"interventions":1799},[75],[1779],[1763,1781],{"trials":1801,"activeCount":85},[],{"trials":1803,"activeCount":85},[],{"trials":1805,"activeCount":85},[],{"intervention":1807,"totalTrials":116,"cells":1808},"Trivalent P2-VP8 Subunit Rotavirus Vaccine",{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1813,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1810,"activeCount":85},[],{"trials":1812,"activeCount":85},[],{"trials":1814,"activeCount":85},[1815],{"nctId":1816,"briefTitle":1817,"status":93,"phases":1818,"primaryCompletion":1819,"completion":1820,"start":1821,"enrollment":1822,"conditions":1823,"interventions":1825},"NCT02646891","Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants",[74,75],"2017-09-01","2017-12-22","2016-02-15",618,[1824],"Healthy",[1807],{"trials":1827,"activeCount":85},[],{"trials":1829,"activeCount":85},[],{"trials":1831,"activeCount":85},[],{"intervention":1178,"totalTrials":116,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1844,"PHASE4":1846,"NA":1848},{"trials":1835,"activeCount":85},[],{"trials":1837,"activeCount":85},[],{"trials":1839,"activeCount":85},[1840],{"nctId":1168,"briefTitle":1169,"status":93,"phases":1841,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":1174,"conditions":1842,"interventions":1843},[74,75],[1176],[1178,1179,1080],{"trials":1845,"activeCount":85},[],{"trials":1847,"activeCount":85},[],{"trials":1849,"activeCount":85},[],{"intervention":1179,"totalTrials":116,"cells":1851},{"EARLY_PHASE1":1852,"PHASE1":1854,"PHASE2":1856,"PHASE3":1862,"PHASE4":1864,"NA":1866},{"trials":1853,"activeCount":85},[],{"trials":1855,"activeCount":85},[],{"trials":1857,"activeCount":85},[1858],{"nctId":1168,"briefTitle":1169,"status":93,"phases":1859,"primaryCompletion":1171,"completion":1172,"start":1173,"enrollment":1174,"conditions":1860,"interventions":1861},[74,75],[1176],[1178,1179,1080],{"trials":1863,"activeCount":85},[],{"trials":1865,"activeCount":85},[],{"trials":1867,"activeCount":85},[],{"intervention":1137,"totalTrials":116,"cells":1869},{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1874,"PHASE3":1880,"PHASE4":1882,"NA":1884},{"trials":1871,"activeCount":85},[],{"trials":1873,"activeCount":85},[],{"trials":1875,"activeCount":85},[1876],{"nctId":1127,"briefTitle":1128,"status":93,"phases":1877,"primaryCompletion":1130,"completion":1131,"start":1132,"enrollment":1133,"conditions":1878,"interventions":1879},[75],[1135],[1137,1138,1118,1139,1140],{"trials":1881,"activeCount":85},[],{"trials":1883,"activeCount":85},[],{"trials":1885,"activeCount":85},[],{"intervention":1138,"totalTrials":116,"cells":1887},{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1892,"PHASE3":1898,"PHASE4":1900,"NA":1902},{"trials":1889,"activeCount":85},[],{"trials":1891,"activeCount":85},[],{"trials":1893,"activeCount":85},[1894],{"nctId":1127,"briefTitle":1128,"status":93,"phases":1895,"primaryCompletion":1130,"completion":1131,"start":1132,"enrollment":1133,"conditions":1896,"interventions":1897},[75],[1135],[1137,1138,1118,1139,1140],{"trials":1899,"activeCount":85},[],{"trials":1901,"activeCount":85},[],{"trials":1903,"activeCount":85},[],{"intervention":1139,"totalTrials":116,"cells":1905},{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1910,"PHASE3":1916,"PHASE4":1918,"NA":1920},{"trials":1907,"activeCount":85},[],{"trials":1909,"activeCount":85},[],{"trials":1911,"activeCount":85},[1912],{"nctId":1127,"briefTitle":1128,"status":93,"phases":1913,"primaryCompletion":1130,"completion":1131,"start":1132,"enrollment":1133,"conditions":1914,"interventions":1915},[75],[1135],[1137,1138,1118,1139,1140],{"trials":1917,"activeCount":85},[],{"trials":1919,"activeCount":85},[],{"trials":1921,"activeCount":85},[],{"intervention":1140,"totalTrials":116,"cells":1923},{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1934,"PHASE4":1936,"NA":1938},{"trials":1925,"activeCount":85},[],{"trials":1927,"activeCount":85},[],{"trials":1929,"activeCount":85},[1930],{"nctId":1127,"briefTitle":1128,"status":93,"phases":1931,"primaryCompletion":1130,"completion":1131,"start":1132,"enrollment":1133,"conditions":1932,"interventions":1933},[75],[1135],[1137,1138,1118,1139,1140],{"trials":1935,"activeCount":85},[],{"trials":1937,"activeCount":85},[],{"trials":1939,"activeCount":85},[],{"intervention":1941,"totalTrials":116,"cells":1942},"SIIL LAIV",{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1947,"PHASE3":1957,"PHASE4":1959,"NA":1961},{"trials":1944,"activeCount":85},[],{"trials":1946,"activeCount":85},[],{"trials":1948,"activeCount":85},[1949],{"nctId":1950,"briefTitle":1951,"status":93,"phases":1952,"primaryCompletion":744,"completion":744,"start":1953,"enrollment":1954,"conditions":1955,"interventions":1956},"NCT01625689","Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine",[75],"2012-06",309,[20],[1941],{"trials":1958,"activeCount":85},[],{"trials":1960,"activeCount":85},[],{"trials":1962,"activeCount":85},[],{"intervention":1460,"totalTrials":116,"cells":1964},{"EARLY_PHASE1":1965,"PHASE1":1967,"PHASE2":1969,"PHASE3":1975,"PHASE4":1977,"NA":1979},{"trials":1966,"activeCount":85},[],{"trials":1968,"activeCount":85},[],{"trials":1970,"activeCount":85},[1971],{"nctId":1452,"briefTitle":1453,"status":93,"phases":1972,"primaryCompletion":1455,"completion":1456,"start":536,"enrollment":1457,"conditions":1973,"interventions":1974},[74,75],[22],[1460,1422,1461,1462],{"trials":1976,"activeCount":85},[],{"trials":1978,"activeCount":85},[],{"trials":1980,"activeCount":85},[],{"intervention":1461,"totalTrials":116,"cells":1982},{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1993,"PHASE4":1995,"NA":1997},{"trials":1984,"activeCount":85},[],{"trials":1986,"activeCount":85},[],{"trials":1988,"activeCount":85},[1989],{"nctId":1452,"briefTitle":1453,"status":93,"phases":1990,"primaryCompletion":1455,"completion":1456,"start":536,"enrollment":1457,"conditions":1991,"interventions":1992},[74,75],[22],[1460,1422,1461,1462],{"trials":1994,"activeCount":85},[],{"trials":1996,"activeCount":85},[],{"trials":1998,"activeCount":85},[],{"intervention":1462,"totalTrials":116,"cells":2000},{"EARLY_PHASE1":2001,"PHASE1":2003,"PHASE2":2005,"PHASE3":2011,"PHASE4":2013,"NA":2015},{"trials":2002,"activeCount":85},[],{"trials":2004,"activeCount":85},[],{"trials":2006,"activeCount":85},[2007],{"nctId":1452,"briefTitle":1453,"status":93,"phases":2008,"primaryCompletion":1455,"completion":1456,"start":536,"enrollment":1457,"conditions":2009,"interventions":2010},[74,75],[22],[1460,1422,1461,1462],{"trials":2012,"activeCount":85},[],{"trials":2014,"activeCount":85},[],{"trials":2016,"activeCount":85},[],{"intervention":604,"totalTrials":116,"cells":2018},{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2023,"PHASE3":2029,"PHASE4":2031,"NA":2033},{"trials":2020,"activeCount":85},[],{"trials":2022,"activeCount":85},[],{"trials":2024,"activeCount":85},[2025],{"nctId":596,"briefTitle":597,"status":93,"phases":2026,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":2027,"interventions":2028},[75],[20],[604,587,605],{"trials":2030,"activeCount":85},[],{"trials":2032,"activeCount":85},[],{"trials":2034,"activeCount":85},[],{"intervention":605,"totalTrials":116,"cells":2036},{"EARLY_PHASE1":2037,"PHASE1":2039,"PHASE2":2041,"PHASE3":2047,"PHASE4":2049,"NA":2051},{"trials":2038,"activeCount":85},[],{"trials":2040,"activeCount":85},[],{"trials":2042,"activeCount":85},[2043],{"nctId":596,"briefTitle":597,"status":93,"phases":2044,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":2045,"interventions":2046},[75],[20],[604,587,605],{"trials":2048,"activeCount":85},[],{"trials":2050,"activeCount":85},[],{"trials":2052,"activeCount":85},[],{"intervention":2054,"totalTrials":116,"cells":2055},"A",{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2070,"PHASE4":2072,"NA":2074},{"trials":2057,"activeCount":85},[],{"trials":2059,"activeCount":85},[],{"trials":2061,"activeCount":85},[2062],{"nctId":2063,"briefTitle":2064,"status":93,"phases":2065,"primaryCompletion":1110,"completion":1110,"start":2066,"enrollment":14,"conditions":2067,"interventions":2069},"NCT02153671","Immunogenicity of H5N1 Vaccine Following H5N2",[75],"2014-05",[2068],"Influenza Vaccine",[2054,2054],{"trials":2071,"activeCount":85},[],{"trials":2073,"activeCount":85},[],{"trials":2075,"activeCount":85},[],{"intervention":2077,"totalTrials":81,"cells":2078},"Shigella sonnei 53G",{"EARLY_PHASE1":2079,"PHASE1":2081,"PHASE2":2103,"PHASE3":2105,"PHASE4":2107,"NA":2109},{"trials":2080,"activeCount":85},[],{"trials":2082,"activeCount":85},[2083,2092],{"nctId":2084,"briefTitle":2085,"status":93,"phases":2086,"primaryCompletion":2087,"completion":2087,"start":2088,"enrollment":2089,"conditions":2090,"interventions":2091},"NCT02816346","Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain",[74],"2017-12-31","2016-09-12",56,[1824],[2077],{"nctId":2093,"briefTitle":2094,"status":93,"phases":2095,"primaryCompletion":2096,"completion":2096,"start":2097,"enrollment":2098,"conditions":2099,"interventions":2101},"NCT04992520","Controlled Human Infection Model Challenge\u002FRechallenge",[74],"2023-08-29","2022-04-26",46,[2100],"Shigellosis",[2077,2102],"Shigella flexneri 2a 2457T",{"trials":2104,"activeCount":85},[],{"trials":2106,"activeCount":85},[],{"trials":2108,"activeCount":85},[],{"trials":2110,"activeCount":85},[],{"intervention":2112,"totalTrials":116,"cells":2113},"P2-VP8 subunit rotavirus vaccine",{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2126,"PHASE3":2128,"PHASE4":2130,"NA":2132},{"trials":2115,"activeCount":85},[],{"trials":2117,"activeCount":85},[2118],{"nctId":2119,"briefTitle":2120,"status":93,"phases":2121,"primaryCompletion":537,"completion":599,"start":614,"enrollment":2122,"conditions":2123,"interventions":2125},"NCT01764256","A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine",[74],48,[2124],"Rotavirus Infection",[2112],{"trials":2127,"activeCount":85},[],{"trials":2129,"activeCount":85},[],{"trials":2131,"activeCount":85},[],{"trials":2133,"activeCount":85},[],{"intervention":2135,"totalTrials":116,"cells":2136},"Inactivated Poliomyelitis Vaccine",{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2153,"PHASE3":2155,"PHASE4":2157,"NA":2159},{"trials":2138,"activeCount":85},[],{"trials":2140,"activeCount":85},[2141],{"nctId":2142,"briefTitle":2143,"status":93,"phases":2144,"primaryCompletion":2145,"completion":2145,"start":2146,"enrollment":2147,"conditions":2148,"interventions":2150},"NCT04232943","Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults",[74],"2021-02-01","2020-01-22",87,[2149],"Polio",[2135,2151,2152],"E.coli Double Mutant Heat-Labile Toxin","Bivalent Oral Polio Vaccine",{"trials":2154,"activeCount":85},[],{"trials":2156,"activeCount":85},[],{"trials":2158,"activeCount":85},[],{"trials":2160,"activeCount":85},[],{"intervention":2151,"totalTrials":116,"cells":2162},{"EARLY_PHASE1":2163,"PHASE1":2165,"PHASE2":2171,"PHASE3":2173,"PHASE4":2175,"NA":2177},{"trials":2164,"activeCount":85},[],{"trials":2166,"activeCount":85},[2167],{"nctId":2142,"briefTitle":2143,"status":93,"phases":2168,"primaryCompletion":2145,"completion":2145,"start":2146,"enrollment":2147,"conditions":2169,"interventions":2170},[74],[2149],[2135,2151,2152],{"trials":2172,"activeCount":85},[],{"trials":2174,"activeCount":85},[],{"trials":2176,"activeCount":85},[],{"trials":2178,"activeCount":85},[],{"intervention":2152,"totalTrials":116,"cells":2180},{"EARLY_PHASE1":2181,"PHASE1":2183,"PHASE2":2189,"PHASE3":2191,"PHASE4":2193,"NA":2195},{"trials":2182,"activeCount":85},[],{"trials":2184,"activeCount":85},[2185],{"nctId":2142,"briefTitle":2143,"status":93,"phases":2186,"primaryCompletion":2145,"completion":2145,"start":2146,"enrollment":2147,"conditions":2187,"interventions":2188},[74],[2149],[2135,2151,2152],{"trials":2190,"activeCount":85},[],{"trials":2192,"activeCount":85},[],{"trials":2194,"activeCount":85},[],{"trials":2196,"activeCount":85},[],{"intervention":2198,"totalTrials":116,"cells":2199},"IVACFLU",{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2212,"PHASE3":2214,"PHASE4":2216,"NA":2218},{"trials":2201,"activeCount":85},[],{"trials":2203,"activeCount":85},[2204],{"nctId":2205,"briefTitle":2206,"status":93,"phases":2207,"primaryCompletion":2208,"completion":614,"start":2209,"enrollment":2122,"conditions":2210,"interventions":2211},"NCT01507779","Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine",[74],"2012-11","2012-04",[20],[2198],{"trials":2213,"activeCount":85},[],{"trials":2215,"activeCount":85},[],{"trials":2217,"activeCount":85},[],{"trials":2219,"activeCount":85},[],{"intervention":2221,"totalTrials":116,"cells":2222},"LAIV H5N2",{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2234,"PHASE3":2236,"PHASE4":2238,"NA":2240},{"trials":2224,"activeCount":85},[],{"trials":2226,"activeCount":85},[2227],{"nctId":2228,"briefTitle":2229,"status":93,"phases":2230,"primaryCompletion":991,"completion":991,"start":536,"enrollment":2231,"conditions":2232,"interventions":2233},"NCT01719783","Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine",[74],40,[20],[2221],{"trials":2235,"activeCount":85},[],{"trials":2237,"activeCount":85},[],{"trials":2239,"activeCount":85},[],{"trials":2241,"activeCount":85},[],{"intervention":2243,"totalTrials":116,"cells":2244},"Vaccine: 2.6±0.8 x 10^8 vp\u002FmL, 1 dose",{"EARLY_PHASE1":2245,"PHASE1":2247,"PHASE2":2260,"PHASE3":2262,"PHASE4":2264,"NA":2266},{"trials":2246,"activeCount":85},[],{"trials":2248,"activeCount":85},[2249],{"nctId":2250,"briefTitle":2251,"status":93,"phases":2252,"primaryCompletion":614,"completion":614,"start":2253,"enrollment":2254,"conditions":2255,"interventions":2256},"NCT01509846","Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults",[74],"2011-03",82,[2100],[2243,2257,2258,2259],"Vaccine: 2.6±0.8 x 10^9 vp\u002FmL, 3 doses","Vaccine: 2.6±0.8 x 10^10 vp\u002FmL, 3 doses","Vaccine: 2.6±0.8 x 10^11 vp\u002FmL, 3 doses",{"trials":2261,"activeCount":85},[],{"trials":2263,"activeCount":85},[],{"trials":2265,"activeCount":85},[],{"trials":2267,"activeCount":85},[],{"intervention":2257,"totalTrials":116,"cells":2269},{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2278,"PHASE3":2280,"PHASE4":2282,"NA":2284},{"trials":2271,"activeCount":85},[],{"trials":2273,"activeCount":85},[2274],{"nctId":2250,"briefTitle":2251,"status":93,"phases":2275,"primaryCompletion":614,"completion":614,"start":2253,"enrollment":2254,"conditions":2276,"interventions":2277},[74],[2100],[2243,2257,2258,2259],{"trials":2279,"activeCount":85},[],{"trials":2281,"activeCount":85},[],{"trials":2283,"activeCount":85},[],{"trials":2285,"activeCount":85},[],{"intervention":2258,"totalTrials":116,"cells":2287},{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2296,"PHASE3":2298,"PHASE4":2300,"NA":2302},{"trials":2289,"activeCount":85},[],{"trials":2291,"activeCount":85},[2292],{"nctId":2250,"briefTitle":2251,"status":93,"phases":2293,"primaryCompletion":614,"completion":614,"start":2253,"enrollment":2254,"conditions":2294,"interventions":2295},[74],[2100],[2243,2257,2258,2259],{"trials":2297,"activeCount":85},[],{"trials":2299,"activeCount":85},[],{"trials":2301,"activeCount":85},[],{"trials":2303,"activeCount":85},[],{"intervention":2259,"totalTrials":116,"cells":2305},{"EARLY_PHASE1":2306,"PHASE1":2308,"PHASE2":2314,"PHASE3":2316,"PHASE4":2318,"NA":2320},{"trials":2307,"activeCount":85},[],{"trials":2309,"activeCount":85},[2310],{"nctId":2250,"briefTitle":2251,"status":93,"phases":2311,"primaryCompletion":614,"completion":614,"start":2253,"enrollment":2254,"conditions":2312,"interventions":2313},[74],[2100],[2243,2257,2258,2259],{"trials":2315,"activeCount":85},[],{"trials":2317,"activeCount":85},[],{"trials":2319,"activeCount":85},[],{"trials":2321,"activeCount":85},[],{"intervention":2102,"totalTrials":116,"cells":2323},{"EARLY_PHASE1":2324,"PHASE1":2326,"PHASE2":2332,"PHASE3":2334,"PHASE4":2336,"NA":2338},{"trials":2325,"activeCount":85},[],{"trials":2327,"activeCount":85},[2328],{"nctId":2093,"briefTitle":2094,"status":93,"phases":2329,"primaryCompletion":2096,"completion":2096,"start":2097,"enrollment":2098,"conditions":2330,"interventions":2331},[74],[2100],[2077,2102],{"trials":2333,"activeCount":85},[],{"trials":2335,"activeCount":85},[],{"trials":2337,"activeCount":85},[],{"trials":2339,"activeCount":85},[],{"intervention":2341,"totalTrials":116,"cells":2342},"Shigella sonnei Strain WRSS1 Vaccine",{"EARLY_PHASE1":2343,"PHASE1":2345,"PHASE2":2356,"PHASE3":2358,"PHASE4":2360,"NA":2362},{"trials":2344,"activeCount":85},[],{"trials":2346,"activeCount":85},[2347],{"nctId":2348,"briefTitle":2349,"status":93,"phases":2350,"primaryCompletion":2351,"completion":2351,"start":2352,"enrollment":2353,"conditions":2354,"interventions":2355},"NCT02934178","Shigella WRSS1 Vaccine Trial in Bangladesh",[74],"2018-01-10","2017-02-23",16,[22],[2341],{"trials":2357,"activeCount":85},[],{"trials":2359,"activeCount":85},[],{"trials":2361,"activeCount":85},[],{"trials":2363,"activeCount":85},[],{"intervention":2365,"totalTrials":116,"cells":2366},"cH8\u002F1N1 LAIV",{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2387,"PHASE3":2389,"PHASE4":2391,"NA":2393},{"trials":2368,"activeCount":85},[],{"trials":2370,"activeCount":85},[2371],{"nctId":2372,"briefTitle":2373,"status":93,"phases":2374,"primaryCompletion":2375,"completion":2376,"start":2377,"enrollment":2378,"conditions":2379,"interventions":2381},"NCT03300050","Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine",[74],"2018-04-24","2019-08-09","2017-10-10",65,[20,2380],"Vaccine",[2365,2382,2383,2384,2385,2386],"AS03-adjuvanted cH5\u002F1N1 IIV","cH5\u002F1N1 IIV","AS03-adjuvanted cH8\u002F1N1 IIV","Normal saline","Phosphate buffered saline",{"trials":2388,"activeCount":85},[],{"trials":2390,"activeCount":85},[],{"trials":2392,"activeCount":85},[],{"trials":2394,"activeCount":85},[],{"intervention":2382,"totalTrials":116,"cells":2396},{"EARLY_PHASE1":2397,"PHASE1":2399,"PHASE2":2405,"PHASE3":2407,"PHASE4":2409,"NA":2411},{"trials":2398,"activeCount":85},[],{"trials":2400,"activeCount":85},[2401],{"nctId":2372,"briefTitle":2373,"status":93,"phases":2402,"primaryCompletion":2375,"completion":2376,"start":2377,"enrollment":2378,"conditions":2403,"interventions":2404},[74],[20,2380],[2365,2382,2383,2384,2385,2386],{"trials":2406,"activeCount":85},[],{"trials":2408,"activeCount":85},[],{"trials":2410,"activeCount":85},[],{"trials":2412,"activeCount":85},[],{"intervention":2383,"totalTrials":116,"cells":2414},{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2423,"PHASE3":2425,"PHASE4":2427,"NA":2429},{"trials":2416,"activeCount":85},[],{"trials":2418,"activeCount":85},[2419],{"nctId":2372,"briefTitle":2373,"status":93,"phases":2420,"primaryCompletion":2375,"completion":2376,"start":2377,"enrollment":2378,"conditions":2421,"interventions":2422},[74],[20,2380],[2365,2382,2383,2384,2385,2386],{"trials":2424,"activeCount":85},[],{"trials":2426,"activeCount":85},[],{"trials":2428,"activeCount":85},[],{"trials":2430,"activeCount":85},[],{"intervention":2384,"totalTrials":116,"cells":2432},{"EARLY_PHASE1":2433,"PHASE1":2435,"PHASE2":2441,"PHASE3":2443,"PHASE4":2445,"NA":2447},{"trials":2434,"activeCount":85},[],{"trials":2436,"activeCount":85},[2437],{"nctId":2372,"briefTitle":2373,"status":93,"phases":2438,"primaryCompletion":2375,"completion":2376,"start":2377,"enrollment":2378,"conditions":2439,"interventions":2440},[74],[20,2380],[2365,2382,2383,2384,2385,2386],{"trials":2442,"activeCount":85},[],{"trials":2444,"activeCount":85},[],{"trials":2446,"activeCount":85},[],{"trials":2448,"activeCount":85},[],{"intervention":2385,"totalTrials":116,"cells":2450},{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2459,"PHASE3":2461,"PHASE4":2463,"NA":2465},{"trials":2452,"activeCount":85},[],{"trials":2454,"activeCount":85},[2455],{"nctId":2372,"briefTitle":2373,"status":93,"phases":2456,"primaryCompletion":2375,"completion":2376,"start":2377,"enrollment":2378,"conditions":2457,"interventions":2458},[74],[20,2380],[2365,2382,2383,2384,2385,2386],{"trials":2460,"activeCount":85},[],{"trials":2462,"activeCount":85},[],{"trials":2464,"activeCount":85},[],{"trials":2466,"activeCount":85},[],{"intervention":2386,"totalTrials":116,"cells":2468},{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2477,"PHASE3":2479,"PHASE4":2481,"NA":2483},{"trials":2470,"activeCount":85},[],{"trials":2472,"activeCount":85},[2473],{"nctId":2372,"briefTitle":2373,"status":93,"phases":2474,"primaryCompletion":2375,"completion":2376,"start":2377,"enrollment":2378,"conditions":2475,"interventions":2476},[74],[20,2380],[2365,2382,2383,2384,2385,2386],{"trials":2478,"activeCount":85},[],{"trials":2480,"activeCount":85},[],{"trials":2482,"activeCount":85},[],{"trials":2484,"activeCount":85},[],{"intervention":2486,"totalTrials":116,"cells":2487},"Invaplex[AR-DETOX]",{"EARLY_PHASE1":2488,"PHASE1":2490,"PHASE2":2501,"PHASE3":2503,"PHASE4":2505,"NA":2507},{"trials":2489,"activeCount":85},[],{"trials":2491,"activeCount":85},[2492],{"nctId":2493,"briefTitle":2494,"status":93,"phases":2495,"primaryCompletion":2496,"completion":2496,"start":2497,"enrollment":2498,"conditions":2499,"interventions":2500},"NCT03869333","Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]",[74],"2020-06-12","2019-03-18",58,[22],[2486],{"trials":2502,"activeCount":85},[],{"trials":2504,"activeCount":85},[],{"trials":2506,"activeCount":85},[],{"trials":2508,"activeCount":85},[],{"intervention":2510,"totalTrials":116,"cells":2511},"LAIV H7N3",{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2523,"PHASE3":2525,"PHASE4":2527,"NA":2529},{"trials":2513,"activeCount":85},[],{"trials":2515,"activeCount":85},[2516],{"nctId":2517,"briefTitle":2518,"status":93,"phases":2519,"primaryCompletion":1953,"completion":548,"start":2209,"enrollment":2231,"conditions":2520,"interventions":2522},"NCT01511419","Safety Trial of Live Attenuated Influenza (H7N3) Vaccine",[74],[20,2521],"Avian Influenza",[2510],{"trials":2524,"activeCount":85},[],{"trials":2526,"activeCount":85},[],{"trials":2528,"activeCount":85},[],{"trials":2530,"activeCount":85},[],{"intervention":2532,"totalTrials":116,"cells":2533},"Adjuvanted MCV-5",{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2550,"PHASE3":2552,"PHASE4":2554,"NA":2556},{"trials":2535,"activeCount":85},[],{"trials":2537,"activeCount":85},[2538],{"nctId":2539,"briefTitle":2540,"status":93,"phases":2541,"primaryCompletion":2542,"completion":2542,"start":2543,"enrollment":2544,"conditions":2545,"interventions":2547},"NCT02810340","Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults",[74],"2017-10-13","2016-08-01",60,[2546],"Meningococcal Vaccines",[2532,2548,2549],"Non-Adjuvanted MCV-5","Menactra®",{"trials":2551,"activeCount":85},[],{"trials":2553,"activeCount":85},[],{"trials":2555,"activeCount":85},[],{"trials":2557,"activeCount":85},[],{"intervention":2548,"totalTrials":116,"cells":2559},{"EARLY_PHASE1":2560,"PHASE1":2562,"PHASE2":2568,"PHASE3":2570,"PHASE4":2572,"NA":2574},{"trials":2561,"activeCount":85},[],{"trials":2563,"activeCount":85},[2564],{"nctId":2539,"briefTitle":2540,"status":93,"phases":2565,"primaryCompletion":2542,"completion":2542,"start":2543,"enrollment":2544,"conditions":2566,"interventions":2567},[74],[2546],[2532,2548,2549],{"trials":2569,"activeCount":85},[],{"trials":2571,"activeCount":85},[],{"trials":2573,"activeCount":85},[],{"trials":2575,"activeCount":85},[],{"intervention":2549,"totalTrials":116,"cells":2577},{"EARLY_PHASE1":2578,"PHASE1":2580,"PHASE2":2586,"PHASE3":2588,"PHASE4":2590,"NA":2592},{"trials":2579,"activeCount":85},[],{"trials":2581,"activeCount":85},[2582],{"nctId":2539,"briefTitle":2540,"status":93,"phases":2583,"primaryCompletion":2542,"completion":2542,"start":2543,"enrollment":2544,"conditions":2584,"interventions":2585},[74],[2546],[2532,2548,2549],{"trials":2587,"activeCount":85},[],{"trials":2589,"activeCount":85},[],{"trials":2591,"activeCount":85},[],{"trials":2593,"activeCount":85},[],{"intervention":179,"totalTrials":116,"cells":2595},{"EARLY_PHASE1":2596,"PHASE1":2598,"PHASE2":2604,"PHASE3":2606,"PHASE4":2608,"NA":2610},{"trials":2597,"activeCount":85},[],{"trials":2599,"activeCount":85},[2600],{"nctId":171,"briefTitle":172,"status":93,"phases":2601,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":2602,"interventions":2603},[74],[24],[51,179,180,181],{"trials":2605,"activeCount":85},[],{"trials":2607,"activeCount":85},[],{"trials":2609,"activeCount":85},[],{"trials":2611,"activeCount":85},[],{"intervention":180,"totalTrials":116,"cells":2613},{"EARLY_PHASE1":2614,"PHASE1":2616,"PHASE2":2622,"PHASE3":2624,"PHASE4":2626,"NA":2628},{"trials":2615,"activeCount":85},[],{"trials":2617,"activeCount":85},[2618],{"nctId":171,"briefTitle":172,"status":93,"phases":2619,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":2620,"interventions":2621},[74],[24],[51,179,180,181],{"trials":2623,"activeCount":85},[],{"trials":2625,"activeCount":85},[],{"trials":2627,"activeCount":85},[],{"trials":2629,"activeCount":85},[],{"intervention":181,"totalTrials":116,"cells":2631},{"EARLY_PHASE1":2632,"PHASE1":2634,"PHASE2":2640,"PHASE3":2642,"PHASE4":2644,"NA":2646},{"trials":2633,"activeCount":85},[],{"trials":2635,"activeCount":85},[2636],{"nctId":171,"briefTitle":172,"status":93,"phases":2637,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":2638,"interventions":2639},[74],[24],[51,179,180,181],{"trials":2641,"activeCount":85},[],{"trials":2643,"activeCount":85},[],{"trials":2645,"activeCount":85},[],{"trials":2647,"activeCount":85},[],{"intervention":1437,"totalTrials":116,"cells":2649},{"EARLY_PHASE1":2650,"PHASE1":2652,"PHASE2":2658,"PHASE3":2660,"PHASE4":2662,"NA":2664},{"trials":2651,"activeCount":85},[],{"trials":2653,"activeCount":85},[2654],{"nctId":1429,"briefTitle":1430,"status":93,"phases":2655,"primaryCompletion":1432,"completion":1432,"start":1433,"enrollment":1434,"conditions":2656,"interventions":2657},[74],[22],[1437,1422],{"trials":2659,"activeCount":85},[],{"trials":2661,"activeCount":85},[],{"trials":2663,"activeCount":85},[],{"trials":2665,"activeCount":85},[],{"intervention":2667,"totalTrials":116,"cells":2668},"LAIV H2N2",{"EARLY_PHASE1":2669,"PHASE1":2671,"PHASE2":2680,"PHASE3":2682,"PHASE4":2684,"NA":2686},{"trials":2670,"activeCount":85},[],{"trials":2672,"activeCount":85},[2673],{"nctId":2674,"briefTitle":2675,"status":93,"phases":2676,"primaryCompletion":1456,"completion":1713,"start":1455,"enrollment":2677,"conditions":2678,"interventions":2679},"NCT01982331","Reactogenicity, Safety and Immunogenicity of a Live Monovalent A\u002F17\u002FCALIFORNIA\u002F66\u002F395 (H2N2) Influenza Vaccine",[74],38,[20],[2667],{"trials":2681,"activeCount":85},[],{"trials":2683,"activeCount":85},[],{"trials":2685,"activeCount":85},[],{"trials":2687,"activeCount":85},[],{"intervention":2689,"totalTrials":116,"cells":2690},"SPWCV+Alum 100 mcg",{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2707,"PHASE3":2709,"PHASE4":2711,"NA":2713},{"trials":2692,"activeCount":85},[],{"trials":2694,"activeCount":85},[2695],{"nctId":2696,"briefTitle":2697,"status":93,"phases":2698,"primaryCompletion":2699,"completion":600,"start":2700,"enrollment":2701,"conditions":2702,"interventions":2704},"NCT01537185","Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults",[74],"2012-10","2012-02",42,[2703],"Pneumococcal Vaccines",[2689,2705,2706],"SPWCV+Alum 600 mcg","SPWCV+Alum 300 mcg",{"trials":2708,"activeCount":85},[],{"trials":2710,"activeCount":85},[],{"trials":2712,"activeCount":85},[],{"trials":2714,"activeCount":85},[],{"intervention":2705,"totalTrials":116,"cells":2716},{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2725,"PHASE3":2727,"PHASE4":2729,"NA":2731},{"trials":2718,"activeCount":85},[],{"trials":2720,"activeCount":85},[2721],{"nctId":2696,"briefTitle":2697,"status":93,"phases":2722,"primaryCompletion":2699,"completion":600,"start":2700,"enrollment":2701,"conditions":2723,"interventions":2724},[74],[2703],[2689,2705,2706],{"trials":2726,"activeCount":85},[],{"trials":2728,"activeCount":85},[],{"trials":2730,"activeCount":85},[],{"trials":2732,"activeCount":85},[],{"intervention":2706,"totalTrials":116,"cells":2734},{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2743,"PHASE3":2745,"PHASE4":2747,"NA":2749},{"trials":2736,"activeCount":85},[],{"trials":2738,"activeCount":85},[2739],{"nctId":2696,"briefTitle":2697,"status":93,"phases":2740,"primaryCompletion":2699,"completion":600,"start":2700,"enrollment":2701,"conditions":2741,"interventions":2742},[74],[2703],[2689,2705,2706],{"trials":2744,"activeCount":85},[],{"trials":2746,"activeCount":85},[],{"trials":2748,"activeCount":85},[],{"trials":2750,"activeCount":85},[],{"intervention":1330,"totalTrials":31,"cells":2752},{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2759,"PHASE4":2765,"NA":2777},{"trials":2754,"activeCount":85},[],{"trials":2756,"activeCount":85},[],{"trials":2758,"activeCount":85},[],{"trials":2760,"activeCount":85},[2761],{"nctId":1322,"briefTitle":1323,"status":93,"phases":2762,"completion":1325,"start":1326,"enrollment":1327,"conditions":2763,"interventions":2764},[76],[30],[1330,1311],{"trials":2766,"activeCount":85},[2767],{"nctId":2768,"briefTitle":2769,"status":93,"phases":2770,"primaryCompletion":2771,"completion":2772,"start":2773,"enrollment":2774,"conditions":2775,"interventions":2776},"NCT00604955","Expand Access\u002FAssess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis",[77],"2008-12","2010-01","2007-10",2000,[30],[1330],{"trials":2778,"activeCount":85},[2779],{"nctId":2780,"briefTitle":2781,"status":93,"phases":2782,"primaryCompletion":2783,"completion":1953,"start":2784,"enrollment":2785,"conditions":2786,"interventions":2787},"NCT01328457","An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh",[78],"2011-05","2011-01",120,[30],[1330],{"intervention":105,"totalTrials":31,"cells":2789},{"EARLY_PHASE1":2790,"PHASE1":2792,"PHASE2":2794,"PHASE3":2800,"PHASE4":2802,"NA":2808},{"trials":2791,"activeCount":85},[],{"trials":2793,"activeCount":85},[],{"trials":2795,"activeCount":85},[2796],{"nctId":91,"briefTitle":92,"status":93,"phases":2797,"primaryCompletion":95,"completion":96,"start":97,"enrollment":98,"conditions":2798,"interventions":2799},[75],[100],[102,103,41,104,105],{"trials":2801,"activeCount":85},[],{"trials":2803,"activeCount":85},[2804],{"nctId":960,"briefTitle":961,"status":962,"phases":2805,"primaryCompletion":964,"completion":965,"start":966,"enrollment":967,"conditions":2806,"interventions":2807},[77],[969,27],[971,947],{"trials":2809,"activeCount":85},[2810],{"nctId":2811,"briefTitle":2812,"status":93,"phases":2813,"primaryCompletion":2814,"completion":2814,"start":2815,"enrollment":2701,"conditions":2816,"interventions":2817},"NCT04666350","Clinical Investigation Study to Evaluate the Consistency and Reproducibility of Two Consecutive Mosquito Feeding Assays",[],"2021-12-20","2021-03-09",[17],[105,2818],"Artemether\u002FLumefantrine",{"intervention":2820,"totalTrials":116,"cells":2821},"MDA with DHAp",{"EARLY_PHASE1":2822,"PHASE1":2824,"PHASE2":2826,"PHASE3":2828,"PHASE4":2830,"NA":2832},{"trials":2823,"activeCount":85},[],{"trials":2825,"activeCount":85},[],{"trials":2827,"activeCount":85},[],{"trials":2829,"activeCount":85},[],{"trials":2831,"activeCount":85},[],{"trials":2833,"activeCount":85},[2834],{"nctId":2835,"briefTitle":2836,"status":93,"phases":2837,"primaryCompletion":2838,"completion":2839,"start":1110,"enrollment":2840,"conditions":2841,"interventions":2843},"NCT02329301","Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia",[78],"2016-06","2020-08",2430,[17,2842],"Malaria, Falciparum",[2820,2844],"Focal MDA with DHAp",{"intervention":2844,"totalTrials":116,"cells":2846},{"EARLY_PHASE1":2847,"PHASE1":2849,"PHASE2":2851,"PHASE3":2853,"PHASE4":2855,"NA":2857},{"trials":2848,"activeCount":85},[],{"trials":2850,"activeCount":85},[],{"trials":2852,"activeCount":85},[],{"trials":2854,"activeCount":85},[],{"trials":2856,"activeCount":85},[],{"trials":2858,"activeCount":85},[2859],{"nctId":2835,"briefTitle":2836,"status":93,"phases":2860,"primaryCompletion":2838,"completion":2839,"start":1110,"enrollment":2840,"conditions":2861,"interventions":2862},[78],[17,2842],[2820,2844],{"intervention":2864,"totalTrials":116,"cells":2865},"Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine",{"EARLY_PHASE1":2866,"PHASE1":2868,"PHASE2":2870,"PHASE3":2872,"PHASE4":2874,"NA":2876},{"trials":2867,"activeCount":85},[],{"trials":2869,"activeCount":85},[],{"trials":2871,"activeCount":85},[],{"trials":2873,"activeCount":85},[],{"trials":2875,"activeCount":85},[],{"trials":2877,"activeCount":85},[2878],{"nctId":2879,"briefTitle":2880,"status":93,"phases":2881,"primaryCompletion":2772,"completion":2772,"start":2773,"enrollment":2882,"conditions":2883,"interventions":2885},"NCT00524745","Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil",[78],903,[2884],"Dose Schedule Study",[2864],{"intervention":2818,"totalTrials":116,"cells":2887},{"EARLY_PHASE1":2888,"PHASE1":2890,"PHASE2":2892,"PHASE3":2894,"PHASE4":2896,"NA":2898},{"trials":2889,"activeCount":85},[],{"trials":2891,"activeCount":85},[],{"trials":2893,"activeCount":85},[],{"trials":2895,"activeCount":85},[],{"trials":2897,"activeCount":85},[],{"trials":2899,"activeCount":85},[2900],{"nctId":2811,"briefTitle":2812,"status":93,"phases":2901,"primaryCompletion":2814,"completion":2814,"start":2815,"enrollment":2701,"conditions":2902,"interventions":2903},[],[17],[105,2818],{"intervention":2905,"totalTrials":116,"cells":2906},"Tenofovir",{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2911,"PHASE3":2913,"PHASE4":2915,"NA":2917},{"trials":2908,"activeCount":85},[],{"trials":2910,"activeCount":85},[],{"trials":2912,"activeCount":85},[],{"trials":2914,"activeCount":85},[],{"trials":2916,"activeCount":85},[],{"trials":2918,"activeCount":85},[2919],{"nctId":2920,"briefTitle":2921,"status":93,"phases":2922,"primaryCompletion":2923,"completion":2923,"start":2784,"enrollment":2924,"conditions":2925,"interventions":2927},"NCT01283555","Comparative Safety Study of Two Vaginal Applicators With Tenofovir",[78],"2011-06",25,[2926],"Microbicide Applicator",[2905],{"intervention":2929,"totalTrials":116,"cells":2930},"WRSS1",{"EARLY_PHASE1":2931,"PHASE1":2933,"PHASE2":2935,"PHASE3":2937,"PHASE4":2939,"NA":2941},{"trials":2932,"activeCount":85},[],{"trials":2934,"activeCount":85},[],{"trials":2936,"activeCount":85},[],{"trials":2938,"activeCount":85},[],{"trials":2940,"activeCount":85},[],{"trials":2942,"activeCount":85},[2943],{"nctId":2944,"briefTitle":2945,"status":93,"phases":2946,"primaryCompletion":1171,"completion":1171,"start":2947,"enrollment":2948,"conditions":2949,"interventions":2950},"NCT01813071","Safety Study of Live Attenuated Oral Shigella (WRSS1) Vaccine in Bangladeshi Adults and Children",[78],"2013-08",103,[22],[2929]]